H.C. Wainwright raised the firm's price target on Absci to $16 from $8 and keeps a Buy rating on the shares. The firm now includes ABS-201 endometriosis sales into the model, with an overall risk-adjusted peak-sales estimate of $549M. Absci reported positive interim results from the blinded single ascending dose portion of the Phase 1/2a HEADLINE study evaluating ABS-201 in 32 healthy volunteers, some of whom had androgenetic alopecia, the analyst tells investors in a research note.
